Gilead Sciences Q3 revenues up 8%
Gilead posted a net income of $704.88m for the third quarter 2010, or $0.83 per diluted share, compared to $673.03m, or $0.72 per diluted share, for the comparable
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
Topical Interferon Alpha-2b incorporates Helix BioPharma’s proprietary Biphasix drug delivery technology, designed to offer a superior means of delivering interferon-alpha-2b therapeutically to HPV-infected tissues. Helix BioPharma said that